Treating Patients With RCC Who Progress Following Adjuvant Therapy
The expert panel concludes with insights on the treatment of patients with renal cell carcinoma who progress following adjuvant therapy.
RCC: Informing Treatment Decisions with Clinical Trial Data
Experts on renal cell carcinoma discuss how clinical trial data inform treatment decisions, highlighting the negative results from PROSPER, CheckMate 914 Part A, and IMmotion010.
KEYNOTE-564: Adjuvant Pembrolizumab in Renal Cell Carcinoma
Dr Pal discusses the study design and results of the KEYNOTE-564 trial, and Benjamin Gerendash, MSN, RN, AGACNP-BC, discusses the management of adverse events associated with pembrolizumab.
ARASENS Trial- Darolutamide in mHSPC
May 15th 2024Dr. Shore will provide an overview of the Phase 3 ARASENS trial, which evaluated the efficacy of the androgen receptor inhibitor darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel in hormone-sensitive prostate cancer patients. He will discuss the potential benefits of this combination in patients with high tumor burden mHSPC.
Treatment Intensification in Metastatic Prostate Cancer
May 15th 2024Dr. Shore will explore the evidence supporting treatment intensification through combining or sequencing therapies in metastatic prostate cancer. He will discuss the potential benefits and downsides of this approach, as well as which patients may benefit from an intensified treatment strategy.
Case 2: A 48-Year-Old Man with Renal Cell Carcinoma
Sumanta Kumar Pal, MD, FASCO, presents the case of a 48-year-old man with renal cell carcinoma, and Rana R. McKay, MD, discusses how she discusses risk of recurrence with patients.
Emerging Therapies for Refractory cGvHD: Potential Advantages of Axatilimab
May 3rd 2024The final segment explores the potential role of axatilimab, a novel agent, in the management of refractory cGvHD, highlighting its mechanism of action and potential efficacy compared to existing treatment options.
Quality of Life + Clinical Monitoring Outside the Transplant Center
April 30th 2024Yi-Bin Chen, MD, proposes a strategy to enhance patients' quality of life by utilizing virtual monitoring as an alternative to requiring patients to travel to a transplant center, which includes regular remote assessments of blood work, such as liver function tests, lipid panels, and immunoglobulin levels.
Second-Line Medications and Toxicities in GVHD
April 30th 2024A medical expert delves into various aspects of second-line therapies, including dose reductions, potential adverse reactions, and the possibility of transfusions, all of which are important considerations when managing patients on second-line treatments.
Adverse Event Profile and Tolerability of Fruquintinib Based on FRESCO-2 Trial
April 25th 2024Arvind Dasari, MD, explores the adverse event profile of Fruquintinib, highlighting its apparent tolerability, while emphasizing the importance of gathering real-world data to further assess the adverse event profile of this medication in clinical practice.
FRESCO-2 Study Design Overview
April 25th 2024Medical professionals provide background on the FRESCO-2 trial, which compared Fruquintinib to placebo in patients with heavily pretreated metastatic colorectal cancer. The trial enrolled patients who had exhausted all standard treatment options, including cytotoxic chemotherapy, targeted therapies, anti-VEGF agents, and BRAF inhibitors for those with BRAF mutations.
Updates on the iNTEGRATE and ROCKstar Trials
April 23rd 2024Yi-Bin Chen, MD, provides an overview of the iNTEGRATE and ROCKstar trials, underscoring their significance in the current treatment paradigm for graft versus host disease, particularly highlighting their ability to inhibit the fibrosis cascade, which offers substantial benefits for patient healing and recovery.
Setting Expectations + First-Line and Second-Line Treatment of Graft Versus Host Disease
April 16th 2024A medical professional outlines the goals and challenges of communicating with his patient, emphasizing the importance of setting realistic expectations for halting disease progression and potentially achieving some degree of disease reversibility, while also exploring the roles of first-line and second-line therapies in the management of chronic graft versus host disease.
Patient Case: Pathology of Graft Versus Host Disease
April 16th 2024Yi-Bin Chen, MD, presents a patient case, detailing the symptomology and pathology of graft versus host disease, such as dry eyes, dry mouth, and difficulty swallowing, while also addressing steroid dependence as an indication for initiating second-line therapy.